Federal Trade Commission and seven states had accused Shkreli, the founder of Vyera Pharmaceuticals, of using illegal tactics to keep Daraprim rivals out of the market.
She said the Daraprim scheme was "particularly heartless and coercive," and a lifetime industry ban was needed because of the "real danger" that Shkreli could become a repeat offender.Regulators accused Vyera of protecting its dominance of Daraprim by ensuring that generic drugmakers could not obtain samples for cheaper versions, and keeping potential rivals from buying a key ingredient